PW Medtech Group Limited provided group revenue guidance for the six months ended June 30, 2020. The board of directors of the company informed the shareholders of the company and the potential investors that, based on the information currently available to the Board, including the latest unaudited management accounts of the Group for the five months ended May 31, 2020, the Group is expected to record a significant decrease in the revenue from the Group's infusion set business for the six months ended June 30, 2020 in the range of 35% to 45% as compared with RMB 172.3 million for the same period of last year.